HLA-G and neoplasm: Decitabine treatment increased HLA-G expression in tumor cells and enhanced recognition of these cells by specific CD4+ helper T lymphocytes, suggesting a combination of decitabine with HLA-G targeting to improve T cell-based immunotherapy [122].